A BMD threshold for treatment efficacy in osteoporosis? A need to consider the whole evidence base

Osteoporosis International

Volumn 27, Issue 1, 2016, Pages 417-419

  McCloskey, E ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BACITRACIN METHYLENE DISALICYLATE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; ESTROGEN; GESTAGEN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

DRUG EFFICACY; FEMUR NECK; FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; LETTER; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SPINE FRACTURE; HIP FRACTURES; INAPPROPRIATE PRESCRIBING;

HIP FRACTURES; HUMANS; INAPPROPRIATE PRESCRIBING; OSTEOPOROSIS;

EID: 84955209398     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3406-5     Document Type: Letter

References (22)

1. Uzoigwe CE (2015) The real enemy is fragility fracture, not osteoporosis. Osteoporos Int. doi:10.1007/s00198-015-3405-6
2. Oden A, McCloskey EV, Johansson H, Kanis JA (2013) Assessing the impact of osteoporosis on the burden of hip fractures. Calcif Tissue Int 92(1):42–9
3. Jarvinen TL, Michaelsson K, Jokihaara J et al (2015) Overdiagnosis of bone fragility in the quest to prevent hip fracture. BMJ 350:h2088
4. Ensrud KE, Black DM, Palermo L et al (1997) Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 157(22):2617–24
5. Roux C, Reginster JY, Fechtenbaum J et al (2006) Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 21(4):536–42
6. Kanis JA, Barton IP, Johnell O (2005) Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporos Int 16(5):475–82
7. McCloskey E, Selby P, Davies M et al (2004) Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 19(5):728–36
8. Eastell R, Black DM, Boonen S et al (2009) Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab 94(9):3215–25
9. McClung M, Boonen S, Torring O et al (2011) Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 27:211–218
10. Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280(24):2077–82
11. McCloskey EV, Beneton M, Charlesworth D et al (2007) Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 22(1):135–41
12. McCloskey EV, Johansson H, Oden A et al (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 27(7):1480–6
13. Cauley JA, Robbins J, Chen Z et al (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290(13):1729–38
14. Gnant M, Pfeifer G, Dubsky PC, et al (2015) Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial.Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial. American Society of Clinical Oncology, J Clin Oncol 33, 2015 (suppl; abstr 504)
15. Johansson H, Kanis JA, Oden A, Johnell O, McCloskey E (2009) BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int 20(10):1675–82
16. Kanis JA, on behalf of the WHO Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. Sheffield: WHO Collaborating Centre, University of Sheffield, UK
17. Johansson H, Oden A, Johnell O et al (2004) Optimization of BMD measurements to identify high risk groups for treatment—a test analysis. J Bone Miner Res 19(6):906–13
18. Leslie WD, Morin S, Lix LM et al (2012) Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int 23(1):75–85
19. Leslie WD, Majumdar SR, Lix LM et al (2012) High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos Int 23(1):391–7
20. McCloskey EV, Johansson H, Oden A et al (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20(5):811–7
21. Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44(6):1049–54
22. Boonen S, Black DM, Colon-Emeric CS et al (2010) Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 58(2):292–9